Skip to content
Home/Companies/Healthcare / Biotech/Ermium
Ermium

Ermium

Healthcare / Biotech·France·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Ermium?

Ermium is currently owned by Eurazeo through Kurma Biofund III (2017 vintage), since 2019.

Hand-verified · updated 2026-04-21

Eurazeo
Investor
Eurazeo
Kurma Biofund III · 2017 · Healthcare

Key facts

HQFrance
SectorHealthcare / Biotech
Websiteermium.com

More from Kurma Biofund III

Other portfolio companies in the same fund.

ImCheck
ImCheck
Exited 2025
BiotechFrance· 2020
to
Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2019
to
IO Biotech
IO Biotech
Active
BiotechDenmark· 2019
Pharvaris
Pharvaris
Active
BiotechNetherlands· 2019
Vivet
Vivet
Active
BiotechFrance· 2019
Orphazyme
Orphazyme
Active
BiotechDenmark· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Ermium

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Ermium.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue